Results 111 to 120 of about 27,163 (253)

Diagnoses of Multiple Sclerosis and Related Disorders and Disease‐Modifying Therapies: A Comparison of the Danish Multiple Sclerosis Registry With Other Danish Health Registries

Brain and Behavior, Volume 16, Issue 2, February 2026.
This study aimed to describe and compare information on diagnoses of MS and related disorders as well as treatments with disease‐modifying therapies (DMTs) available in three national registries, highlighting the key differences relevant to MS research.
Hanna Joensen, Elisabeth Framke, Luigi Pontieri, Melinda Magyari   +3 more
wiley   +1 more source

Multiple Sklerose im Kindes- und Jugendalter: Fingolimod versus Interferon beta-1a [PDF]

, 2019

openalex   +1 more source

Comorbidities at MS Diagnosis and Their Association With Treatment Persistence: Real‐World Clinical Data

Brain and Behavior, Volume 16, Issue 2, February 2026.
Comorbidity was present in approximately half of the patients with relapsing‐remitting multiple sclerosis in this Finnish cross‐sectional cohort. Comorbidities, especially psychiatric diseases, were associated with lower persistence on injectable disease‐modifying treatments.
Henrik Ahvenjärvi, Ida Lund, Anne M. Portaankorva, Johanna Krüger, Mervi Ryytty   +4 more
wiley   +1 more source

Effetti cardiaci degli agonisti della sfingosina: monitoraggio in una coorte di pazienti con sclerosi multipla. [PDF]

, 2016
Fingolimod è il primo trattamento orale approvato per la Sclerosi Multipla (SM). Si tratta di un analogo della sfingosina e lega il recettore della sfingosina 1-fosfato (S1P1) bloccando cosi la fuoriuscita dei linfociti dai linfonodi riducendo gli ...
BLINOVA, YULIA
core  

IMST-43. A TOXICITY ASSESSMENT OF BRAIN RADIATION AND FINGOLIMOD IN AN ANIMAL MODEL OF TREATMENT-RELATED LYMPHOPENIA [PDF]

, 2016
Anna F. Piotrowski, D'Vone C. Jackson
openalex   +1 more source

Targeting Staphylococcus aureus Biofilms Through Aurisin Derivatives From Neonothopanus nambi of African Origin

Chemistry &Biodiversity, Volume 23, Issue 2, February 2026.
This study describes the isolation and characterization of potent bioactive compounds from the fungal strain Neonothopanus nambi, followed by structural elucidation. The compounds shown are dimeric aristolane‐type sesquiterpenoids, identified as aurisins D (1) and B (2).
Syeda J. Khalid, Njogu M. Kimani, Yuanyuyue Huang, Mathias Müsken, Jan‐Peer Wennrich, Jonas Bentrup, Miroslav Kolařík, Josphat Clemet Matasyoh, Hedda Schrey   +8 more
wiley   +1 more source

Fingolimod attenuates experimental autoimmune neuritis and contributes to Schwann cell-mediated axonal protection

Journal of Neuroinflammation, 2017
Background Fingolimod, a sphingosine-1-phosphate receptor modulator with well-described immunomodulatory properties involving peripheral immune cell trafficking, was the first oral agent approved for the treatment of relapsing remitting multiple ...
Björn Ambrosius, Kalliopi Pitarokoili, Lisa Schrewe, Xiomara Pedreiturria, Jeremias Motte, Ralf Gold   +5 more
doaj   +1 more source

CD56bright NK cells are negatively associated with antibody response to vaccination in people with multiple sclerosis on B‐cell‐depleting therapy

Clinical &Translational Immunology, Volume 15, Issue 2, 2026.
Antibody response to vaccination in people with multiple sclerosis receiving B‐cell depletion therapy is associated with B‐cell frequency but not time since B‐cell depletion. Immunoregulatory CD56bright NK cells may negatively impact antibody responses in this group.
Griffith B Perkins, Christopher M Hope, Cheng Sheng Chai, Matthew J Tunbridge, Sebastian Sterling, Kevin Webb, Joey Yap, Arthur Eng Lip Yeow, Makutiro G Masavuli, Jacqueline Scaffidi, James D Zuiani, Anouschka Akerman, Anupriya Aggarwal, Vanessa Milogiannakis, Matthew B Roberts, Plinio R Hurtado, Stuart Turville, Branka Grubor‐Bauk, Simon C Barry, Janakan Ravindran, Patrick Toby Coates, Pravin Hissaria   +21 more
wiley   +1 more source

Disease reactivation in a patient with secondary progressive multiple sclerosis after switching treatment from fingolimod to siponimod

, 2021
Kensuke Senzaki, Hirofumi Ochi, Masayuki Ochi, Yôko Okada, Shiroh Miura, Yasumasa Ohyagi   +5 more
openalex   +1 more source

Metabolic reprogramming of efferocytosis in the tumour microenvironment: From apoptotic‐cell clearance to therapeutic targeting

Clinical and Translational Medicine, Volume 16, Issue 2, February 2026.
This review systematically deconstructs the pathological efferocytic—metabolic axis in tumours, framing it as a three‐stage, self‐reinforcing cycle: from metabolite‐driven macrophage recruitment, through hijacked surface recognition, to post‐phagocytic metabolic reprogramming that locks in immunosuppression.
Qianlu Yang, Jie Yan, Qianxi Yang
wiley   +1 more source